

Treatment tied to survival benefit in complex bladder cancer

17 October 2018



"These data provide a foundation for future work aimed at personalizing the <u>treatment</u> guidance of older patients with <u>cancer</u> with MCC," the authors write.

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

(HealthDay)—Cancer treatment is associated with a clinically meaningful survival benefit in older, medically complex patients with superficial bladder cancer (SBC), according to a study published online Oct. 5 in *Cancer*.

Tullika Garg, M.D., M.P.H., from Geisinger in Danville, Pa., and colleagues evaluated the association between treatment of SBC and 10-year mortality in 1,800 medically complex patients aged ?60 years.

Overall, 1,485 patients (82.5 percent) received treatment and 315 patients (17.5 percent) underwent observation. The researchers found that treatment was associated with a 30 percent reduction in death, while having multiple complex conditions (MCC) was associated with a 72 percent increase in death in unweighted multivariable analysis. There was also a survival benefit for treatment in weighted analysis with adjustment (adjusted hazard ratio, 0.66).



APA citation: Treatment tied to survival benefit in complex bladder cancer (2018, October 17) retrieved 12 June 2022 from https://medicalxpress.com/news/2018-10-treatment-tied-survival-benefit-complex.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.